Clinical Trial Search

Primary: Actigraphically-Derived Total Sleep Time — 5.03; 11.44; 7.60; 17.96 Minutes

Primary: Serum Testosterone (ng/dL) Days 9 and 10 Average (Rounded-up), CR-ITT — 1.0000; 1.0000 ng/dL

Primary: Safety Endpoint 1: Percentages of Subjects With Solicited Local and Systemic Adverse Events (AEs) — 32; 33; 32; 34 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0; 0 Participants

Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 241; 38…

Primary: Delay in Therapy — 11.73; 10.89 min per 24 hours

Primary: Number of Participants With DLTs to Determine the MTD — 0; 0; 0; 1 Participants

Primary: Change in Direct-measured LDL-C — -3.80; 2.95; 4.36; -1.70 mg/dL — p=0.0167

Primary: Two-way Crossover Period: Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo) — 227.0186; 238.2725 nanograms (ng)/milliliter (mL)

Primary: Evaluate the Efficacy of RBT-1 in Generating a Preconditioning Response as Measured by a Composite of Biomarkers — 3.60; 2.63; 1.00 composite ratio — p=<0.0001

Primary: Percentage of Post-Acute MI Patients Who Are Referred for Sudden Cardiac Death Risk Stratification > Risk (SCD) Stratification and Management — 236; 934 Participants

Primary: Total Average Anesthetic — 1.1890; 1.2906 percentage of sevoflurane

Primary: Maternal Emotion Dysregulation — 82.35; 91.8 score on a scale — p=.002

Primary: Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A — 2.45; 1.84 Units on a Scale

Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg